In the present study, we have synthesized
poly(styrene-co-maleic anhydride), a biocompatible copolymer that was further conjugated with
paclitaxel (PTX) via
ester linkage and self-assembled to form
poly(styrene-co-maleic acid)-
paclitaxel (PSMAC-PTX) nanoparticles (NPs). The in vitro release of PTX from PSMAC-PTX NPs showed a higher release at lower pH than at the physiological pH of 7.4, confirming its pH-dependent release. The cell viability of PSMAC-PTX nanoparticles was evaluated using MTT assay. IC50 values of 9.05-18.43 ng/mL of PTX equivalent were observed in various
cancer cell lines after 72 h of incubation. Confocal microscopy, Western blotting, and Flow cytometry results further supported that the cellular uptake and apoptosis of
cancer cells with PSMAC-PTX NPs. Pharmacokinetic studies revealed that the conjugation of PTX to the PSMAC co-
polymer not only increased the plasma and
tumor C(max) of PTX but also prolonged its plasma half-life and retention in
tumor via enhanced permeability and retention (EPR) effect. Administration of PSMAC-PTX NPs showed significant
tumor growth inhibition with improved apoptosis effects in vivo on
Ehrlich Ascites Tumor (EAT)-bearing BALB/c syngeneic mice in comparison with
Taxol, without showing any cytotoxicity. On the basis of preliminary results, no subacute toxicity was observed in major organs, tissues and hematological system up to a dosage of 60 mg/kg
body weight in mice. Therefore, PSMAC-PTX NPs may be considered as an alternative nanodrug delivery system for the delivery of PTX in solid
tumors.